[1]
|
方三高, 陈真伟, 魏建国. 2021年第5版WHO胸部肿瘤分类[J]. 诊断病理学杂志, 2021, 28(7): 591-593+607.
|
[2]
|
Baldovini, C., Rossi, G. and Ciarrocchi, A. (2019) Approaches to Tumor Classification in Pulmo-nary Sarcomatoid Carcinoma. Lung Cancer (Auckl), 10, 131-149. https://doi.org/10.2147/LCTT.S186779
|
[3]
|
Sun, J.C., Jiang, Z.Y., Shan, T.Y., Yang, R.N., Kong, D.J., Rui, J.S., Li, X.Y., Kong, G.Q. and Chang, B.P. (2022) Charac-teristics and Prognostic Analysis of 55 Patients with Pulmonary Sarcomatoid Carcinoma. Frontiers in Oncology, 12, Ar-ticle ID: 833486. https://doi.org/10.3389/fonc.2022.833486
|
[4]
|
Hou, J.N., Xing, L.H. and Yuan, Y.F. (2018) A Clinical Analysis of 114 Cases of Sarcomatoid Carcinoma of the Lung. Clinical Experimental Medical, 18, 555-562. https://doi.org/10.1007/s10238-018-0517-2
|
[5]
|
Liu, X., Wang, F., Chen, X., Hou, X., Li, Q., Xie, Z., Liu, Y., et al. (2021) P35.01 Genomic Origin and Immune-Related Status of Pulmonary Sarcomatoid Carcinoma. Journal of Tho-racic Oncology, 16, S419.
https://doi.org/10.1016/j.jtho.2021.01.702
|
[6]
|
Duma, N., Santana-Davila, R. and Molina, J.R. (2019) Non-Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment. Mayo Clinic Proceedings, 94, 1623-1640. https://doi.org/10.1016/j.mayocp.2019.01.013
|
[7]
|
Yoshino, N., Kubokura, H., Yamauchi, S., Ohaki, Y., Koizumi, K. and Shimizu, K. (2009) A True Pulmonary Carcinosarcoma That Required Diagnostic Differentiation from a Pleo-morphic Adenoma: A Case Report. Annals of Thoracic and Cardiovascular Surgery, 15, 42-45.
|
[8]
|
Ung, M., Rouquette, I., Filleron, T., Taillandy, K., Brouchet, L., Bennouna, J., et al. (2016) Characteristics and Clinical Outcomes of Sarcomatoid Carcinoma of the Lung. Clinical Lung Cancer, 17, 391-397.
https://doi.org/10.1016/j.cllc.2016.03.001
|
[9]
|
Xu, X.-L., Song, W., Sui, X., Song, L., Wang, X., Feng, R.-E. and Li, Y. (2016) Computed Tomographic and Pathological Features of Primary Pulmonary Sarcomatoid Carcinoma. Acta Academiae Medicinae Sinicae, 38, 93-98.
|
[10]
|
张新东, 张谷青, 陈月芹. 肺肉瘤样癌的CT诊断及误诊分析[J]. 医学影像学杂志, 2014, 24(4): 531-533+552.
|
[11]
|
Rapicetta, C., Lococo, F., Stefani, A., Rossi, G., Ricchetti, T., Filice, A., et al. (2016) Primary Sarcomatoid Carcinoma of the Lung: Radiometabolic ((18)F-FDG PET/CT) Findings and Cor-relation with Clinico-Pathological and Survival Results. Lung, 194, 653-657. https://doi.org/10.1007/s00408-016-9904-1
|
[12]
|
王雷, 李向平, 孙健, 李超, 张海滨. 肺癌肉瘤11例临床分析[J]. 临床荟萃, 2010, 25(23): 2080-2082.
|
[13]
|
Vohra, A. and Narula, H. (2014) Imaging Findings of Pulmonary Car-cinosarcoma: A Case Report. Lung India, 31, 164-167. https://doi.org/10.4103/0970-2113.129861
|
[14]
|
Xu, L., Tao, N.-N., Liang, B., Li, D.-W., Li, H.-C. and Su, L.-L. (2022) Use of PD-1 Inhibitor Tislelizumab in the Treatment of Ad-vanced Pulmonary Sarcomatoid Carcinoma: A Case Report. Thoracic Cancer, 13, 502-505.
https://doi.org/10.1111/1759-7714.14290
|
[15]
|
Pelosi, G., Sonzogni, A., De Pas, T., Galetta, D., Veronesi, G., Spaggiari, L., et al. (2010) Review Article: Pulmonary Sarcomatoid Carcinomas: A Practical Overview. International Journal of Surgical Pathology, 18, 103-120.
https://doi.org/10.1177/1066896908330049
|
[16]
|
Takeshima, Y., Amatya, V.J., Kushitani, K., Kaneko, M. and Inai, K. (2009) Value of Immunohistochemistry in the Differential Diagnosis of Pleural Sarcomatoid Mesothelioma from Lung Sarcomatoid Carcinoma. Histopathology, 54, 667-676. https://doi.org/10.1111/j.1365-2559.2009.03298.x
|
[17]
|
吕冬亮, 张玲红, 戴丹丹, 王春, 杨汉卿. 肺肉瘤样癌11例CT表现及鉴别诊断[J]. 中国乡村医药, 2018, 25(21): 46-47.
|
[18]
|
张卉, 王道清, 程留慧. 原发性肺肉瘤样癌的CT表现及鉴别诊断[J]. 中国中西医结合影像学杂志, 2019, 17(6): 625-627.
|
[19]
|
Rahouma, M., Kamel, M., Narula, N., Nasar, A., Harrison, S., Lee, B., et al. (2018) Pulmo-nary Sarcomatoid Carcinoma: An Analysis of a Rare Cancer from the Surveillance, Epidemiology, and End Results Da-tabase. European Association for Cardio-Thoracic Surgery, 53, 828-834. https://doi.org/10.1093/ejcts/ezx417
|
[20]
|
杨文静, 张百华, 王永岗, 张宏图. 肺癌肉瘤13例临床分析[J]. 实用癌症杂志, 2012, 27(5): 506-509.
|
[21]
|
Chaft, J.E., Sima, C.S., Ginsberg, M.S., Huang, J., Kris, M.G., Travis, W.D. and Azzoli, C.G. (2012) Clinical Outcomes with Perioperative Chemotherapy in Sarcomatoid Carcinomas of the Lung. Journal of Thoracic Oncology, 7, 1400-1405. https://doi.org/10.1097/JTO.0b013e3182614856
|
[22]
|
Abdallah, H.M., Martinez-Meehan, D., Lutfi, W., Dhupar, R., Grenda, T., Schuchert, M.J., et al. (2021) Adjuvant Chemotherapy for Pulmonary Sarcomatoid Carcinoma: A Retrospec-tive Analysis of the National Cancer Database. The Journal of Thoracic and Cardiovascular Surgery, 163, 1669-1681.E3. https://doi.org/10.1016/j.jtcvs.2021.01.081
|
[23]
|
Lin, Y.B., Yang, H., Cai, Q.Q., Wang, D.F., Rao, H.L., Lin, S.X., et al. (2016) Characteristics and Prognostic Analysis of 69 Patients with Pulmonary Sarcomatoid Carci-noma. American Journal of Clinical Oncology, 39, 215-222.
https://doi.org/10.1097/COC.0000000000000101
|
[24]
|
Sun, L.D., Dai, J., Chen, Y., Duan, L., He, W.X., Chen, Q.K., et al. (2020) Pulmonary Sarcomatoid Carcinoma: Experience from SEER Database and Shanghai Pulmonary Hos-pital. The Annals of Thoracic Surgery, 110, 406-413.
https://doi.org/10.1016/j.athoracsur.2020.02.071
|
[25]
|
Vieira, T., Girard, N., Ung, M., Monnet, I., Cazes, A., Bonnette, P., et al. (2013) Efficacy of First-Line Chemotherapy in Patients with Advanced Lung Sarcomatoid Carcinoma. Journal of Thoracic Oncology, 8, 1574-1577.
https://doi.org/10.1097/01.JTO.0000437008.00554.90
|
[26]
|
熊伟杰, 张新星, 黄媚娟, 陈柳, 宋玲玲, 薛建新, 王永生, 卢轴. 32例晚期及术后复发肺肉瘤样癌患者的治疗及生存分析[J]. 四川大学学报(医学版), 2014, 45(2): 320-323.
|
[27]
|
Vieira, T., Antoine, M., Ruppert, A.-M., Fallet, V., Duruisseaux, M., Leprieur, E.G., et al. (2014) Blood Vessel Invasion Is a Major Feature and a Factor of Poor Prognosis in Sarcomatoid Carcinoma of the Lung. Lung Cancer, 85, 276-281. https://doi.org/10.1016/j.lungcan.2014.06.004
|
[28]
|
Socinski, M.A., Nishio, M., Jotte, R.M., Cap-puzzo, F., Orlandi, F., Stroyakovskiy, D., et al. (2021) IMpower150 Final Overall Survival Analyses for Atezolizumab plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC. Journal of Thoracic Oncology, 16, 1909-1924. https://doi.org/10.1016/j.jtho.2021.07.009
|
[29]
|
Pérez-Gutiérrez, L. and Ferrara, N. (2023) Biology and Therapeutic Targeting of Vascular Endothelial Growth Factor A. Nature Reviews Molecular Cell Biology. https://doi.org/10.1038/s41580-023-00631-w
|
[30]
|
Oizumi, S., Takamura, K., Harada, T., Tachihara, M., Morikawa, N., Honda, R., et al. (2022) Phase II Study of Carboplatin-Paclitaxel Alone or with Bevacizumab in Advanced Sarcoma-toid Carcinoma of the Lung: HOT1201/NEJ024. International Journal of Clinical Oncology, 27, 676-683. https://doi.org/10.1007/s10147-021-02113-5
|
[31]
|
李巧珍, 张才金, 王爱民. 阿帕替尼治疗肺巨细胞癌1例并文献复习[J]. 现代肿瘤医学, 2018, 26(4): 530-533.
|
[32]
|
Chen, X.Z. (2019) Anlotinib for Refractory Advanced Non-Small Cell Lung Cancer in China. JAMA Oncology, 5, 116-117. https://doi.org/10.1001/jamaoncol.2018.5526
|
[33]
|
徐涵, 曹雅杰, 周宁宁. 安罗替尼治疗老年晚期肺肉瘤样癌1例[J]. 中华实用诊断与治疗杂志, 2020, 34(10): 1065-1066.
|
[34]
|
Li, J., Liang, H.J., He, J., Sui, X. and Qin, Y.R. (2021) Anlotinib Combined with Chemotherapy for Recurrence of Pulmonary Sarcomatoid Cancer Previously Surgically Treated: A Case Report and Literature Review. Frontiers in Oncology, 11, Article ID: 639168. https://doi.org/10.3389/fonc.2021.639168
|
[35]
|
Shen, E., Xiu, J., Bentley, R., López, G.Y. and Walsh, K.M. (2020) Frequent Mutations of POT1 Distinguish Pulmonary Sarcomatoid Carcinoma from Other Lung Cancer Histologies. Clinical Lung Cancer, 21, e523-e527.
https://doi.org/10.1016/j.cllc.2020.04.002
|
[36]
|
Zhou, F., Huang, Y., Cai, W.J., Li, J., Su, C.X., Ren, S.X., et al. (2021) The Genomic and Immunologic Profiles of Pure Pulmonary Sarcomatoid Carcinoma in Chinese Patients. Lung Cancer, 153, 66-72.
https://doi.org/10.1016/j.lungcan.2021.01.006
|
[37]
|
Yang, Z.L., Xu, J.C., Li, L., Li, R.D., Wang, Y.L., Tian, Y.H., et al. (2020) Integrated Molecular Characterization Reveals Potential Therapeutic Strategies for Pulmonary Sarcomatoid Carcinoma. Nature Communications, 11, Article No. 4878. https://doi.org/10.1038/s41467-020-18702-3
|
[38]
|
Liang, X.H., Li, Q., Xu, B., Hu, S., Wang, Q.Y., Li, Y., et al. (2019) Mutation Landscape and Tumor Mutation Burden Analysis of Chinese Patients with Pulmonary Sarcomatoid Carcinomas. International Journal of Clinical Oncology, 24, 1061-1068. https://doi.org/10.1007/s10147-019-01454-6
|
[39]
|
Schrock, A.B., Li, S.D., Frampton, G.M., Suh, J., Braun, E., Mehra, R., et al. (2017) Pulmonary Sarcomatoid Carcinomas Commonly Harbor Either Potentially Targetable Genomic Alterations or High Tumor Mutational Burden as Observed by Comprehensive Genomic Profiling. Journal of Thoracic Oncology, 12, 932-942.
https://doi.org/10.1016/j.jtho.2017.03.005
|
[40]
|
Marei, H.E., Althani, A., Afifi, N., Hasan, A., Caceci, T., Pozzoli, G., et al. (2021) P53 Signaling in Cancer Progression and Therapy. Cancer Cell International, 21, Article No. 703. https://doi.org/10.1186/s12935-021-02396-8
|
[41]
|
Li, X., Zhang, Z.H., Liu, J.H., Wang, D., Wei, S. and Chen, J. (2018) Molecular Features of Giant-Cell Carcinoma of the Lung: A Case Report and Literature Review. OncoTargets and Therapy, 11, 751-756.
https://doi.org/10.2147/OTT.S150124
|
[42]
|
Canale, M. andrikou, K., Priano, I., Cravero, P., Pasini, L., Urbini, M., et al. (2022) The Role of TP53 Mutations in EGFR-Mutated Non-Small-Cell Lung Cancer: Clinical Significance and Im-plications for Therapy. Cancers (Basel), 14, Article No. 1143. https://doi.org/10.3390/cancers14051143
|
[43]
|
Sabapathy, K. and Lane, D.P. (2018) Therapeutic Targeting of p53: All Mutants Are Equal, but Some Mutants Are More Equal than Others. Nature Reviews Clinical Oncology, 15, 13-30. https://doi.org/10.1038/nrclinonc.2017.151
|
[44]
|
Wang, X.M., Cao, J., Du, W.J., Zhang, W.H. and Cao, S. (2021) Response to Gefitinib/Crizotinib Combination in a Pulmonary Sarcomatoid Carcinoma Patient Harboring Concurrent EGFR Mutation and MET Amplification. Clinical Case Reports, 9, e04487. https://doi.org/10.1002/ccr3.4487
|
[45]
|
Italiano, A., Cortot, A.B., Ilie, M., Martel-Planche, G., Fabas, T., Pop, D., et al. (2009) EGFR and KRAS Status of Primary Sarcomatoid Carcinomas of the Lung: Implications for Anti-EGFR Treatment of a Rare Lung Malignancy. International Journal of Cancer, 125, 2479-2482. https://doi.org/10.1002/ijc.24610
|
[46]
|
Li, X., Wu, D., Liu, H.Y. and Chen, J. (2020) Pulmonary Sarcomatoid Car-cinoma: Progress, Treatment and Expectations. Therapeutic Advances in Medical Oncology, 12, 1-19. https://doi.org/10.1177/1758835920950207
|
[47]
|
Zou, F.W., Xie, G.Y., Ma, J.-A., Zhou, D.-A., Jiang, Y. and Zheng, J.-Y. (2015) Epidermal Growth Factor Receptor Mutation Heterogeneity Analysis of Pulmonary Sarcomatoid Carcinoma Successfully Treated with Erlotinib: A Case Report. Oncology Letters, 9, 2239-2243. https://doi.org/10.3892/ol.2015.3057
|
[48]
|
Lococo, F., Gandolfi, G., Rossi, G., Pinto, C., Rapicetta, C., Cavazza, A., et al. (2016) Deep Sequencing Analysis Reveals That KRAS Mutation Is a Marker of Poor Prognosis in Patients with Pulmonary Sarcomatoid Carcinoma. Journal of Thoracic Oncology, 11, 1282-1292. https://doi.org/10.1016/j.jtho.2016.04.020
|
[49]
|
Fu, Y.L., Wang, A.Q., Zhou, J.Q., Feng, W., Shi, M.H., Xu, X., et al. (2021) Advanced NSCLC Patients with EGFR T790M Harboring TP53 R273C or KRAS G12V Cannot Benefit From Osimertinib Based on a Clinical Multicentre Study by Tissue and Liquid Biopsy. Frontiers in Oncology, 11, Article ID: 621992.
https://doi.org/10.3389/fonc.2021.621992
|
[50]
|
Blair, H.A. (2021) Sotorasib: First Approval. Drugs, 81, 1573-1579. https://doi.org/10.1007/s40265-021-01574-2
|
[51]
|
Reck, M., Carbone, D.P., Garassino, M. and Barlesi, F. (2021) Targeting KRAS in Non-Small-Cell Lung Cancer: Recent Progress and New Approaches. Annals of Oncology, 32, 1101-1110. https://doi.org/10.1016/j.annonc.2021.06.001
|
[52]
|
Arbour, K.C., Jordan, E., Kim, H.R., Dienstag, J., Yu, H.A., Sanchez-Vega, F., et al. (2018) Effects of Co-Occurring Genomic Alterations on Outcomes in Patients with KRAS-Mutant Non-Small Cell Lung Cancer. Clinical Cancer Research, 24, 334-340. https://doi.org/10.1158/1078-0432.CCR-17-1841
|
[53]
|
Vuong, H.G., Ho, A.T.N., Altibi, A.M.A., Nakazawa, T., Katoh, R. and Kondo, T. (2018) Clinicopathological Implications of MET Exon 14 Mutations in Non-Small Cell Lung Cancer—A Systematic Review and Meta-Analysis. Lung Cancer, 123, 76-82. https://doi.org/10.1016/j.lungcan.2018.07.006
|
[54]
|
Liu, X.W., Jia, Y.X., Stoopler, M.B., Shen, Y.F., Cheng, H.Y., Chen, J.L., et al. (2016) Next-Generation Sequencing of Pulmonary Sarcomatoid Carcinoma Reveals High Frequency of Actionable MET Gene Mutations. Journal of Clinical Oncology, 34, 794-802. https://doi.org/10.1200/JCO.2015.62.0674
|
[55]
|
Lu, S., Fang, J., Li, X.Y., Cao, L.J., Zhou, J.Y., Guo, Q.S., et al. (2021) Once-Daily Savolitinib in Chinese Patients with Pulmonary Sarcomatoid Carcinomas and Other Non-Small-Cell Lung Cancers Harbouring MET Exon 14 Skipping Alterations: A Multicentre, Single-Arm, Open-Label, Phase 2 Study. The Lancet Respiratory Medicine, 9, 1154-1164. https://doi.org/10.1016/S2213-2600(21)00084-9
|
[56]
|
Han, S., Fang, J., Lu, S., Wang, L.F., Li, J., Cheng, M., et al. (2019) Response and Acquired Resistance to Savolitinib in a Patient with Pulmonary Sarcomatoid Carcinoma Harboring MET Exon 14 Skipping Mutation: A Case Report. OncoTargets and Therapy, 12, 7323-7328. https://doi.org/10.2147/OTT.S210365
|
[57]
|
Awad, M.M., Oxnard, G.R., Jackman, D.M., Savukoski, D.O., Hall, D., Shivdasani, P., et al. (2016) MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated with Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression. Journal of Clinical Oncology, 34, 721-730.
https://doi.org/10.1200/JCO.2015.63.4600
|
[58]
|
Chen, X.R., Zhang, Y., Lu, J.B., Xu, C.W., Liang, J.Z., Wang, F., et al. (2017) Pulmonary Sarcomatoid Carcinoma with ALK Rear-Rangement: Frequency, Clinical-Pathologic Characteris-tics, and Response to ALK Inhibitor. Translational Oncology, 10, 115-120. https://doi.org/10.1016/j.tranon.2016.11.009
|
[59]
|
D’Antonio, F., De Sanctis, R., Bolengo, I., Destro, A., Rahal, D., De Vincenzo, F. and Santoro, A. (2019) Pulmonary Sarcomatoid Carcinoma Presenting both ALK Rearrangement and PD-L1 High Positivity: A Case Report on the Therapeutic Regimen. Medicine (Baltimore), 98, e16754. https://doi.org/10.1097/MD.0000000000016754
|
[60]
|
Pelosi, G., Gasparini, P., Conte, D., Fabbri, A., Perrone, F., Tamborini, E., et al. (2016) Synergistic Activation upon MET and ALK Coamplification Sustains Targeted Therapy in Sarcomatoid Carcinoma, a Deadly Subtype of Lung Cancer. Journal of Thoracic Oncology, 11, 718-728. https://doi.org/10.1016/j.jtho.2016.01.009
|
[61]
|
Roesel, C., Kambartel, K., Kopeika, U., Berzins, A., Voshaar, T. and Krbek, T. (2019) Lazarus-Type Tumour Response to Therapy with Nivolumab for Sarcomatoid Carcinomas of the Lung. Current Oncology, 26, e270-e273.
https://doi.org/10.3747/co.26.4377
|
[62]
|
Ma, Y., Li, W.S., Li, Z.Z., Chen, J., Wang, H.T., Jiang, T. and Zhu, J.F. (2022) Immunophenotyping of Pulmonary Sarcomatoid Carcinoma. Frontiers in Immunology, 13, Article ID: 976739.
https://doi.org/10.3389/fimmu.2022.976739
|
[63]
|
Qian, X.Y., Wang, Y., Liu, F.R., Yuan, Y., Fang, C., Zhang, X.W., et al. (2022) The Efficacy and Safety Analysis of First-Line Immune Checkpoint Inhibitors in Pulmonary Sarco-matoid Carcinoma. Frontiers in Immunology, 13, Article ID: 956982. https://doi.org/10.3389/fimmu.2022.956982
|
[64]
|
Tancoš, V., Farkašová, A., Kviatkovská, Z., Grendár, M., Líško-vá, A., Huťka, Z. and Plank, L. (2020) Non-Small Cell Lung Carcinomas with a Minor Sarcomatoid Component and Pleomorphic Carcinomas Are Associated with High Expression of Programmed Death Ligand 1. Pathology, Research and Practice, 216, Article ID: 153238.
https://doi.org/10.1016/j.prp.2020.153238
|
[65]
|
Kong, F.W., Wang, W.M., Gong, L.B., Wu, W.B. and Liu, Y.Y. (2020) Anti-PD-1 Antibody Camrelizumab plus Doxorubicin Showed Durable Response in Pulmonary Sarcomatoid Carcinoma: Case Report and Literature Review. Journal of Clinical Pharmacy and Therapeutics, 45, 1489-1496. https://doi.org/10.1111/jcpt.13234
|
[66]
|
Zhou, F., Guo, H.Y., Zhou, X.L., Xie, H.K., Tian, T., Zhao, W.C., et al. (2022) Immune Checkpoint Inhibitors plus Chemotherapy in Patients with Locally Advanced or Metastatic Pulmonary Sarcomatoid Carcinoma: A Multicentric Real-World Study. Therapeutic Advances in Medical Oncology, 14, 1-12.
https://doi.org/10.1177/17588359221136759
|
[67]
|
Diego, S., Roberto, F., Claudia, P., Giuseppe, L.R., Martina, I., Giulia, G., et al. (2019) Immune-Checkpoints Inhibitors in Metastatic Non Small Cell Lung Cancer with Rare Histology. Journal of Clinical Oncology, 37, 9106.
https://doi.org/10.1200/JCO.2019.37.15_suppl.9106
|
[68]
|
Jiao, Y.Y., Liu, M., Luo, N.N., Guo, H. and Li, J.Z. (2021) Successful Treatment of Advanced Pulmonary Sarcomatoid Carcinoma with the PD-1 Inhibitor Toripalimab: A Case Report. Oral Oncology, 112, Article ID: 104992.
https://doi.org/10.1016/j.oraloncology.2020.104992
|
[69]
|
Awobajo, M.D., Vaporciyan, A.A., Lu, C. and Gandhi, S.J. (2020) Stereotactic Body Radiation Therapy (SBRT) in the Management of Pulmonary Spindle Cell Carcinoma. BMJ Case Reports, 13, e234779.
https://doi.org/10.1136/bcr-2020-234779
|
[70]
|
Sukrithan, V., Sandler, J., Gucalp, R., Gralla, R. and Halmos, B. (2019) Immune Checkpoint Blockade Is Associated with Durable Responses in Pulmonary Sarcomatoid Carcinoma. Clinical Lung Cancer, 20, e242-e246.
https://doi.org/10.1016/j.cllc.2018.12.013
|
[71]
|
Li, S.M., Jiang, L., He, Q.M., Wei, W.D., Wang, Y., Zhang, X.K., et al. (2019) The Prognostic Significance of JMJD3 in Primary Sarcomatoid Carcinoma of the Lung, A Rare Subtype of Lung Cancer. OncoTargets and Therapy, 12, 9385-9393. https://doi.org/10.2147/OTT.S225596
|
[72]
|
Taniguchi, H., Takemoto, S., Ozasa, M., Honda, N., Suyama, T., Umeyama, Y., et al. (2021) Remarkable Response to Pembrolizumab with Platinum-Doublet in PD-L1-Low Pulmonary Sarcomatoid Carcinoma: A Case Report. Thoracic Cancer, 12, 1126-1130. https://doi.org/10.1111/1759-7714.13890
|
[73]
|
Lococo, F., Torricelli, F., Rossi, G., Alifano, M., Damotte, D., Rapicetta, C., et al. (2017) Inter-Relationship between PD-L1 Expression and Clinic-Pathological Features and Driver Gene Mutations in Pulmonary Sarcomatoid Carcinomas. Lung Cancer, 113, 93-101. https://doi.org/10.1016/j.lungcan.2017.09.009
|
[74]
|
Yang, Z.L., Xu, J.C., Li, R.D., Gao, Y.B. and He, J. (2019) PD-L1 and CD47 Co-Expression in Pulmonary Sarcomatoid Carcinoma: A Predictor of Poor Prognosis and Potential Targets of Future Combined Immunotherapy. Journal of Cancer Research and Clinical Oncology, 145, 3055-3065. https://doi.org/10.1007/s00432-019-03023-w
|
[75]
|
Salati, M., Baldessari, C., Calabrese, F., Rossi, G., Pettorelli, E., Grizzi, G., et al. (2018) Nivolumab-Induced Impressive Response of Refractory Pulmonary Sarcomatoid Carcinoma with Brain Metastasis. Case Reports in Oncology, 11, 615-621. https://doi.org/10.1159/000492666
|
[76]
|
Nishino, K., Kunimasa, K., Kimura, M., Inoue, T., Tamiya, M., Kuhara, H. and Kumagai, T. (2020) Favorable Response to Pembroli-zumab after Durvalumab Failure in a Stage III Sarcomatoid Carcinoma of the Lung: A Case Report. BMC Pharmacology & Toxicology, 21, Article No. 26. https://doi.org/10.1186/s40360-020-00404-7
|